Jun 30 2008
Sequenom selling stock to wipe out Down syndrome
Last week, Sequenom Inc., a maker of genetic testing, announced their launch of a public offering of 5.5 million of its common shares
According to the AP, “The company also will grant underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock. All of the shares are being offered by Sequenom.”
Sequenom Inc., which makes genetic analysis products, announced earlier in the month that a prenatal test used to detect Down syndrome in a mother’s blood was successful in all 200 samples without any false positives.
Current testing options have a detection rate of between 70 percent and 90 percent, with false-positive rates as high as 5 percent.
Most people would see this as a positive happening. However, with the Down syndrome community under fire by last year’s ACOG’s recommendation that ALL pregnant women be screened for Down syndrome by the 20th week of pregnancy, this is just another step into eugenics for those with Down syndrome.
It isn’t that any of us is actually against prenatal testing. In some cases, prenatal testing is a positive step for the parents who are expecting a child with Down syndrome. However, what the Down syndrome community is against is the way the information is being given.
When a parent receives a diagnoses of Down syndrome, the MAJORITY of OB’s are giving outdated, misinformation. These parents are told their child will be a burden to their family, financially and emotionally. They are told their child will not live a long, fulfilling life. And, most are given the visual of a child who can not think or do for his/herself what-so-ever.
These OB’s PUSH—HARD to get the family to abort their child. Thus the reason for this testing before 20 weeks.
Many OB’s have stated that it is their GOAL to ensure that NO PERSON with Down syndrome is ever BORN! This…is eugenics!
As an advocate for those with Down syndrome and mosaic Down syndrome, we join the ranks to ensure that people with Down syndrome do not become extinct. As for now, with the abortion rate of 95% for those carrying a child with Down syndrome, it is without a doubt, that people with Down syndrome are an endangered species.
Sequenom expects to use proceeds from their stocks to develop diagnostic tests for use on its MassArray system and other platforms, and for general corporate purposes. The company currently has about 45.4 million common shares outstanding.
The only “good” thing about this testing from Sequenom is that it isn’t an amino where the baby is at high risk of dying.
People who are buying this stock are buying shares to wipe out Down syndrome.



